Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines. - Wikidata - wikimedia - TriplyDB

Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines.

Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines.

http://www.wikidata.org/entity/Q38059150

about

PET/CT imaging of Mycobacterium tuberculosis infection Drug-resistant TB: deadly, costly and in need of a vaccine Recent advances towards tuberculosis control: vaccines and biomarkers Randomized, placebo-controlled phase II trial of heat-killed Mycobacterium vaccae (Longcom batch) formulated as an oral pill (V7)Randomized, placebo-controlled Phase II trial of heat-killed Mycobacterium vaccae (Immodulon batch) formulated as an oral pill (V7)Novel vaccination strategies against tuberculosis.Infergen Stimulated Macrophages Restrict Mycobacterium tuberculosis Growth by Autophagy and Release of Nitric Oxide.Use of an Sm-p80-based therapeutic vaccine to kill established adult schistosome parasites in chronically infected baboons.Immunotherapeutic efficacy of recombinant Mycobacterium smegmatis expressing Ag85B-ESAT6 fusion protein against persistent tuberculosis infection in mice High-throughput identification and dendritic cell-based functional validation of MHC class I-restricted Mycobacterium tuberculosis epitopes.Immunotherapy of tuberculosis with Mycobacterium leprae Hsp65 as a DNA vaccine triggers cross-reactive antibodies against mammalian Hsp60 but not pathological autoimmunity.Evaluation of the overall IFN-γ and IL-17 pro-inflammatory responses after DNA therapy of tuberculosis.Host-directed therapy of tuberculosis: what is in it for microRNA?Totally drug-resistant tuberculosis and adjunct therapies.Vaccination against infectious diseases: what is promising?Global Efforts in the Development of Vaccines for Tuberculosis: Requirements for Improved Vaccines Against Mycobacterium tuberculosis.The current status, challenges, and future developments of new tuberculosis vaccines.Design, Synthesis, and Biological Evaluation of 1,4-dihydropyridine Derivatives as Potent Antitubercular Agents.A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis.

P2860

Q26748493-0AB77331-7390-44DF-B252-AABE20FF8B59 Q26765385-F0A2067E-C4B4-4729-8F17-3A93F67A24DF Q26859739-529DF5F0-0C4C-46ED-8B44-F350C9C5235B Q28293125-6158D49E-A2AF-4188-A9D5-0D039DC93BD2 Q28299689-2094D305-5124-4D12-9D6F-C4E5C9ED7FEE Q30363188-6CE35688-602D-441B-A371-2D9F89F2C8AE Q30832644-FAD09F72-C231-42ED-A958-48EC9CAE3435 Q33684408-EDBDDC77-89EE-43CB-8F02-4862C0EB3E6E Q34271591-04CB3339-BC81-448E-AA65-F6AA5A6BD299 Q36972511-3191AB67-6A19-4379-B1A6-E8D2FE2A3AA0 Q36977794-5B4143BC-9BAC-4F31-99F1-ED46518241CD Q37505396-386FA814-5A2B-4AF9-A82E-A5B6F7911E39 Q38196883-6C803E18-FC20-465F-A06B-1C0DD6B26703 Q38210265-220F63AC-3D89-4DEB-A4DA-C2048D3CB2A8 Q38234231-557EA3A1-542F-40D8-BC6A-AB99C24B5486 Q38907507-B1DE698C-3377-4174-A8CB-4FF084F53DF4 Q52337140-3D71734A-90FF-44D4-ABBF-AFBFE0A4117A Q52980622-51348455-FC1D-4DDD-89BC-8D09F4FB8565 Q53689031-1F6BEF8D-4851-4B42-B453-A570DFCCC663

P2860

Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines.

http://www.wikidata.org/entity/Q38059150

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines.

@en

type

label

Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines.

@en

prefLabel

Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines.

@en

P1433

Q38059150-EA16E276-AB7B-4B3A-9F2A-2D6CB6CDAB55

P1476

Q38059150-E3964FC2-442B-434C-8DE5-6D652E64D5B2

P2093

Q38059150-0C205809-D4A1-4A3E-83BE-BF8F31C0C2FC

Q38059150-556B3E17-A6C7-427F-8BD6-0A43397AA8E6

Q38059150-57F53243-7AC1-4401-B628-AA2F806F97A1

Q38059150-78FB7D56-54F9-4CC9-A7AE-29C7E285016C

Q38059150-7CD1B33C-601E-480C-9F0F-80C9FB4AD8A5

Q38059150-AB8B9237-35A2-4325-B362-348C3D1FDC75

Q38059150-AECB9C7B-1A93-41D2-826B-034E72D30F41

Q38059150-B5DD97CC-EE67-4CDB-B7CA-A389E45826DB

Q38059150-CF5733C1-BA7B-460D-8BD7-CBEDC21D4A0B

P2860

Q38059150-0107842F-ACFB-4B4D-9175-6BF8CCDE7F75

Q38059150-0219BB3B-FEC9-4513-856C-A5CCB4EBEC0D

Q38059150-032854DC-BEE4-40A2-9B41-CBC1A5C7BA1F

Q38059150-093CA8AD-F3BE-45E7-A782-44DE4DE0F375

Q38059150-0A2A1AC8-F5FF-4172-A8D2-12ABFBB9D7D4

Q38059150-0EDEF794-6D6A-4724-A2F7-11A19B5CEFAF

Q38059150-1135F588-FBDB-42EB-A7B6-89A677929689

Q38059150-11484DE9-3759-421C-B332-0308A24435C0

Q38059150-11BDC496-F768-48F3-9AB1-D829D629F1EF

Q38059150-131DB4AA-3E17-48E7-8B24-C7D25044EE9E

P2888

Q38059150-8F16B074-D097-441D-8E7B-EF8605A58197

P304

Q38059150-74B726BE-56F1-4E60-B153-8AC6A8EAD944

P31

Q38059150-42BBEF14-774D-4491-A2A8-28DF1081DC41

P356

Q38059150-238D2DD3-4287-4C96-AEE0-96357AF92934

P433

Q38059150-5488661D-EFC5-48CB-84C4-FBC1003576F4

P478

Q38059150-5BDE7ADB-8FFE-4351-A9B3-930C5D2EC92A

P50

Q38059150-35DD9352-E63D-4CDE-ABE3-0ADA46686AB1

Q38059150-664AA523-8EDC-4104-A53C-9FE10DDD13A9

Q38059150-8A39CB1D-E49B-41B6-B7AB-F867F7EFD3BA

Q38059150-C66D4103-7205-4AC1-AB33-F3D8543D4D51

Q38059150-F6B95565-7AED-439F-AEF5-654C952A336D

P577

Q38059150-5AE361B4-C8D7-4717-BC1F-A97D3F7E6FAB

P6179

Q38059150-28000C5E-EE7D-428F-B12C-2E88454F4E2F

P698

Q38059150-4BF7D668-4743-40DD-B473-FEC91EBACF1D

P921

Q38059150-27CE629A-7437-40B6-A959-AB9E437A925A

Q38059150-B6597B2C-D08A-4566-B2E6-A0C841EEFDE7

P356

S00430-012-0278-6

P1433

Medical Microbiology and Immunology

P1476

Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines.

@en

P2093

Alena Skrahina

http://www.w3.org/2001/XMLSchema#string

Ed D L Schmidt

http://www.w3.org/2001/XMLSchema#string

Edita Pimkina

http://www.w3.org/2001/XMLSchema#string

Ildikó Visontai

http://www.w3.org/2001/XMLSchema#string

John L Stanford

http://www.w3.org/2001/XMLSchema#string

Matthias I Gröschel

http://www.w3.org/2001/XMLSchema#string

Rotislav Mitrofanov

http://www.w3.org/2001/XMLSchema#string

Serap Hastürk

http://www.w3.org/2001/XMLSchema#string

Traian Mihaescu

http://www.w3.org/2001/XMLSchema#string

P2860

Lipid body-phagosome interaction in macrophages during infectious diseases: host defense or pathogen survival strategy?

Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis

Mathematical modeling of tuberculosis bacillary counts and cellular populations in the organs of infected mice.

Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB

Tuberculosis vaccines: beyond bacille Calmette-Guerin

Future Vaccination Strategies against Tuberculosis: Thinking outside the Box

Robert Koch and the pressures of scientific research: tuberculosis and tuberculin

Mycobacterium tuberculosis: success through dormancy

Vaccines against tuberculosis: where are we and where do we need to go?

Surgical treatment of drug-resistant tuberculosis

P2888

s00430-012-0278-6

P304

95-104

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00430-012-0278-6

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

202

http://www.w3.org/2001/XMLSchema#string

P50

Stefan Kaufmann

Bouke C de Jong

Pere-Joan Cardona

Tjip S van der Werf

Satria A Prabowo

P577

2012-11-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1044105745

http://www.w3.org/2001/XMLSchema#string

P698

23143437

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

multiple drug resistance